EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sarepta Therapeutics's enterprise value is $10,696 Mil.
Sarepta Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-454 Mil. Therefore, Sarepta Therapeutics's EV-to-EBITDA for today is -23.58.
The historical rank and industry rank for Sarepta Therapeutics's EV-to-EBITDA or its related term are showing as below:
SRPT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -129.91 Med: -13.62 Max: -1.71
Current: -23.58
During the past 13 years, the highest EV-to-EBITDA of Sarepta Therapeutics was -1.71. The lowest was -129.91. And the median was -13.62.
SRPT's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs SRPT: -23.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Sarepta Therapeutics's stock price is $117.30.
Sarepta Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.830. Therefore, Sarepta Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Sarepta Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Sarepta Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sarepta Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's EV-to-EBITDA falls into.
Sarepta Therapeutics EV-to-EBITDA Calculation
Sarepta Therapeutics's EV-to-EBITDA for today is calculated as:
Sarepta Therapeutics's current Enterprise Value is $10,696 Mil.
Sarepta Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-454 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sarepta Therapeutics's PE Ratio for today is calculated as:
Sarepta Therapeutics's share price for today is $117.30.
Sarepta Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Sarepta Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarepta Therapeutics (Sarepta Therapeutics) Business Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRPT has been successfully added to your 